Physician profile
Basel Shoua
NPI 1003260662
$98,188.57
in general payments reported to CMS, 2019-2025
49 companies · $48K in 2025
The $48K reported for 2025 was more than what 96% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $249 · 2020: $40.63 · 2021: $99.95 · 2022: $266 · 2023: $9,937 · 2024: $39K · 2025: $48K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $59K · Consulting Fee: $22K · Travel and Lodging: $9,317 · Food and Beverage: $4,947 · Honoraria: $1,470 · Education: $285.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $59,314.35 |
| Consulting Fee | $22,200.00 |
| Travel and Lodging | $9,316.75 |
| Food and Beverage | $4,946.53 |
| Honoraria | $1,470.00 |
| Education | $285.17 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $65,999.93 | 2023-2025 | Imfinzi, Truqap, Lynparza |
| Stemline Therapeutics INC. | $16,241.47 | 2019-2025 | Elzonris |
| Glaxosmithkline, LLC. | $4,251.39 | 2024-2025 | Jemperli, Ojjaara, Zejula |
| Avyxa Pharma, LLC | $4,139.15 | 2025 | |
| Exelixis INC. | $2,117.41 | 2025 | Cabometyx |
| Incyte Corporation | $1,266.05 | 2019-2025 | Zynyz, Monjuvi, Jakafi |
| Daiichi Sankyo INC. | $752.85 | 2024-2025 | Vanflyta, Enhertu, Datroway |
| Beigene USA, INC. | $698.94 | 2024 | Brukinsa, Tevimbra |
| Sobi, INC | $305.31 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $271.49 | 2024-2025 | |
| Sanofi-Aventis U.S. LLC | $254.93 | 2021-2023 | |
| Merck Sharp & Dohme LLC | $186.75 | 2024 | Keytruda, Welireg, Lynparza |
| Amgen INC. | $160.83 | 2019-2023 | Blincyto, Kyprolis |
| Regeneron Healthcare Solutions, INC. | $142.26 | 2020-2025 | Libtayo |
| Pfizer INC. | $134.56 | 2019-2025 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Basel Shoua listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.